{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:45:43Z","timestamp":1792813543782,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["21K06797"],"award-info":[{"award-number":["21K06797"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["21K06797"],"award-info":[{"award-number":["21K06797"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-76256-6","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T10:02:17Z","timestamp":1729504937000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Model-based meta-analysis of HbA1c reduction across SGLT2 inhibitors using dose adjusted by urinary glucose excretion"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8815-4829","authenticated-orcid":false,"given":"Hiromi","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayana","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0708-2543","authenticated-orcid":false,"given":"Hideki","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6783-4398","authenticated-orcid":false,"given":"Ryota","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamato","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4863-9308","authenticated-orcid":false,"given":"Akihiro","family":"Hisaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"76256_CR1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1172\/jci105534","volume":"46","author":"HS Seltzer","year":"1967","unstructured":"Seltzer, H. S., Allen, E. W., Herron, A. L. Jr. & Brennan, M. T. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J. Clin. Invest. 46, 323\u2013335. https:\/\/doi.org\/10.1172\/jci105534 (1967).","journal-title":"J. Clin. Invest."},{"key":"76256_CR2","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/s0140-6736(09)60619-x","volume":"373","author":"AG Tab\u00e1k","year":"2009","unstructured":"Tab\u00e1k, A. G. et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373, 2215\u20132221. https:\/\/doi.org\/10.1016\/s0140-6736(09)60619-x (2009).","journal-title":"Lancet"},{"key":"76256_CR3","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/j.1742-1241.2008.01829.x","volume":"62","author":"SA Jabbour","year":"2008","unstructured":"Jabbour, S. A. & Goldstein, B. J. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int. J. Clin. Pract. 62, 1279\u20131284. https:\/\/doi.org\/10.1111\/j.1742-1241.2008.01829.x (2008).","journal-title":"Int. J. Clin. Pract."},{"key":"76256_CR4","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1111\/dom.13858","volume":"21","author":"T Yakovleva","year":"2019","unstructured":"Yakovleva, T. et al. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors. Diabetes Obes. Metab. 21, 2684\u20132693. https:\/\/doi.org\/10.1111\/dom.13858 (2019).","journal-title":"Diabetes Obes. Metab."},{"key":"76256_CR5","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.2147\/dddt.S372575","volume":"16","author":"X He","year":"2022","unstructured":"He, X. et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of sotagliflozin after multiple ascending doses in chinese healthy subjects. Drug Des. Devel. Ther. 16, 2967\u20132980. https:\/\/doi.org\/10.2147\/dddt.S372575 (2022).","journal-title":"Drug Des. Devel. Ther."},{"key":"76256_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030555","volume":"7","author":"Y Liang","year":"2012","unstructured":"Liang, Y. et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 7, e30555. https:\/\/doi.org\/10.1371\/journal.pone.0030555 (2012).","journal-title":"PLoS One"},{"key":"76256_CR7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00210-011-0713-z","volume":"385","author":"A Tahara","year":"2012","unstructured":"Tahara, A. et al. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch. Pharmacol. 385, 423\u2013436. https:\/\/doi.org\/10.1007\/s00210-011-0713-z (2012).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"76256_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.pharmthera.2013.04.003","volume":"139","author":"E Kurosaki","year":"2013","unstructured":"Kurosaki, E. & Ogasawara, H. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacol. Ther. 139, 51\u201359. https:\/\/doi.org\/10.1016\/j.pharmthera.2013.04.003 (2013).","journal-title":"Pharmacol. Ther."},{"key":"76256_CR9","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.2337\/db07-1472","volume":"57","author":"S Han","year":"2008","unstructured":"Han, S. et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57, 1723\u20131729. https:\/\/doi.org\/10.2337\/db07-1472 (2008).","journal-title":"Diabetes"},{"key":"76256_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","volume":"14","author":"R Grempler","year":"2012","unstructured":"Grempler, R. et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes. Metab. 14, 83\u201390. https:\/\/doi.org\/10.1111\/j.1463-1326.2011.01517.x (2012).","journal-title":"Diabetes Obes. Metab."},{"key":"76256_CR11","doi-asserted-by":"publisher","first-page":"7828","DOI":"10.1021\/jm300884k","volume":"55","author":"Y Ohtake","year":"2012","unstructured":"Ohtake, Y. et al. Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 55, 7828\u20137840. https:\/\/doi.org\/10.1021\/jm300884k (2012).","journal-title":"J. Med. Chem."},{"key":"76256_CR12","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1021\/jm901893x","volume":"53","author":"H Kakinuma","year":"2010","unstructured":"Kakinuma, H. et al. (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J. Med. Chem. 53, 3247\u20133261. https:\/\/doi.org\/10.1021\/jm901893x (2010).","journal-title":"J. Med. Chem."},{"key":"76256_CR13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1001\/jama.2016.9400","volume":"316","author":"SC Palmer","year":"2016","unstructured":"Palmer, S. C. et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: A meta-analysis. Jama 316, 313\u2013324. https:\/\/doi.org\/10.1001\/jama.2016.9400 (2016).","journal-title":"Jama"},{"key":"76256_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40256-022-00528-7","volume":"22","author":"YN Teo","year":"2022","unstructured":"Teo, Y. N. et al. Effects of sodium\/glucose cotransporter 2 (SGLT2) inhibitors and combined SGLT1\/2 inhibitors on cardiovascular, metabolic, renal, and safety outcomes in patients with diabetes: A network meta-analysis of 111 randomized controlled trials. Am. J. Cardiovasc. Drugs 22, 299\u2013323. https:\/\/doi.org\/10.1007\/s40256-022-00528-7 (2022).","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"76256_CR15","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1111\/dom.14452","volume":"23","author":"FH Shi","year":"2021","unstructured":"Shi, F. H. et al. High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: A meta-analysis of randomized clinical trials. Diabetes Obes. Metab. 23, 2125\u20132136. https:\/\/doi.org\/10.1111\/dom.14452 (2021).","journal-title":"Diabetes Obes. Metab."},{"key":"76256_CR16","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1001\/jama.2010.405","volume":"303","author":"OJ Phung","year":"2010","unstructured":"Phung, O. J., Scholle, J. M., Talwar, M. & Coleman, C. I. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. Jama 303, 1410\u20131418. https:\/\/doi.org\/10.1001\/jama.2010.405 (2010).","journal-title":"Jama"},{"key":"76256_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009417","volume":"6","author":"DS Shyangdan","year":"2016","unstructured":"Shyangdan, D. S., Uthman, O. A. & Waugh, N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open 6, e009417. https:\/\/doi.org\/10.1136\/bmjopen-2015-009417 (2016).","journal-title":"BMJ Open"},{"key":"76256_CR18","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/cpt.1307","volume":"105","author":"A Maloney","year":"2019","unstructured":"Maloney, A., Rosenstock, J. & Fonseca, V. A model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes: Comparison of treatment effects at therapeutic doses. Clin. Pharmacol. Ther. 105, 1213\u20131223. https:\/\/doi.org\/10.1002\/cpt.1307 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"key":"76256_CR19","unstructured":"Kowa Company LSKK. Deberza Tablets 20mg\/Apleway Tablets 20mg (Tofogliflozin hydrate) CTD. (2014)."},{"key":"76256_CR20","unstructured":"Astellas Pharma I. Suglat Tablets 25 mg\/50 mg, CTD (Ipragliflozin L-Proline). CTD 2.7.2. (2014)."},{"key":"76256_CR21","unstructured":"Bristol-Myers KK. Forxiga 5 mg\/10 mg tablets CTD (Dapagliflozin propandiol monohydrate). CTD 2.7.2. (2014)."},{"key":"76256_CR22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/psp4.12934","volume":"12","author":"X Yao","year":"2023","unstructured":"Yao, X. et al. A model-based meta analysis study of sodium glucose co-transporter-2 inhibitors. CPT Pharmacom. Syst. Pharmacol. 12, 487\u2013499. https:\/\/doi.org\/10.1002\/psp4.12934 (2023).","journal-title":"CPT Pharmacom. Syst. Pharmacol."},{"key":"76256_CR23","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.2337\/dc12-2391","volume":"36","author":"D Polidori","year":"2013","unstructured":"Polidori, D. et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 36, 2154\u20132161. https:\/\/doi.org\/10.2337\/dc12-2391 (2013).","journal-title":"Diabetes Care"},{"key":"76256_CR24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1365-2796.2006.01746.x","volume":"261","author":"EM Wright","year":"2007","unstructured":"Wright, E. M., Hirayama, B. A. & Loo, D. F. Active sugar transport in health and disease. J. Intern. Med. 261, 32\u201343. https:\/\/doi.org\/10.1111\/j.1365-2796.2006.01746.x (2007).","journal-title":"J. Intern. Med."},{"key":"76256_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1463-1326.2011.01511.x","volume":"14","author":"RA DeFronzo","year":"2012","unstructured":"DeFronzo, R. A., Davidson, J. A. & Del Prato, S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes. Metab. 14, 5\u201314. https:\/\/doi.org\/10.1111\/j.1463-1326.2011.01511.x (2012).","journal-title":"Diabetes Obes. Metab."},{"key":"76256_CR26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1124\/jpet.116.232025","volume":"358","author":"R Ohgaki","year":"2016","unstructured":"Ohgaki, R. et al. Interaction of the sodium\/glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2. J. Pharmacol. Exp. Ther. 358, 94\u2013102. https:\/\/doi.org\/10.1124\/jpet.116.232025 (2016).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"76256_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molmet.2018.10.009","volume":"19","author":"T Suga","year":"2019","unstructured":"Suga, T. et al. SGLT1 in pancreatic \u03b1 cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels. Mol. Metab. 19, 1\u201312. https:\/\/doi.org\/10.1016\/j.molmet.2018.10.009 (2019).","journal-title":"Mol. Metab."},{"key":"76256_CR28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1464-5491.2010.02941.x","volume":"27","author":"RA DeFronzo","year":"2010","unstructured":"DeFronzo, R. A., Stonehouse, A. H., Han, J. & Wintle, M. E. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet. Med. 27, 309\u2013317. https:\/\/doi.org\/10.1111\/j.1464-5491.2010.02941.x (2010).","journal-title":"Diabet. Med."},{"key":"76256_CR29","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/bcp.13807","volume":"85","author":"H Inoue","year":"2019","unstructured":"Inoue, H. et al. Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis. Br. J. Clin. Pharmacol. 85, 393\u2013402. https:\/\/doi.org\/10.1111\/bcp.13807 (2019).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"76256_CR30","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.clinthera.2014.08.001","volume":"36","author":"A Sarashina","year":"2014","unstructured":"Sarashina, A. et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus. Clin. Ther. 36, 1606\u20131615. https:\/\/doi.org\/10.1016\/j.clinthera.2014.08.001 (2014).","journal-title":"Clin. Ther."},{"key":"76256_CR31","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744 (2019).","journal-title":"N. Engl. J. Med."},{"key":"76256_CR32","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1681\/asn.2021020167","volume":"32","author":"GM Chertow","year":"2021","unstructured":"Chertow, G. M. et al. Effects of dapagliflozin in stage 4 chronic kidney disease. J. Am. Soc. Nephrol. 32, 2352\u20132361. https:\/\/doi.org\/10.1681\/asn.2021020167 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"76256_CR33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12933-019-0903-4","volume":"18","author":"AY Kluger","year":"2019","unstructured":"Kluger, A. Y. et al. Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovasc. Diabetol. 18, 99. https:\/\/doi.org\/10.1186\/s12933-019-0903-4 (2019).","journal-title":"Cardiovasc. Diabetol."},{"key":"76256_CR34","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s13300-017-0276-1","volume":"8","author":"H Brath","year":"2017","unstructured":"Brath, H., Pald\u00e1nius, P. M., Bader, G. & Mathieu, C. Relationship between duration of type 2 diabetes and effectiveness of DPP-4 inhibitor versus sulfonylurea as add-on therapy: A post hoc analysis. Diabetes Ther. 8, 829\u2013836. https:\/\/doi.org\/10.1007\/s13300-017-0276-1 (2017).","journal-title":"Diabetes Ther."},{"key":"76256_CR35","doi-asserted-by":"publisher","first-page":"373","DOI":"10.14740\/jocmr2492w","volume":"8","author":"K Iemitsu","year":"2016","unstructured":"Iemitsu, K. et al. Factors influencing changes in hemoglobin A1c and body weight during treatment of type 2 diabetes with ipragliflozin: Interim analysis of the ASSIGN-K study. J. Clin. Med. Res. 8, 373\u2013378. https:\/\/doi.org\/10.14740\/jocmr2492w (2016).","journal-title":"J. Clin. Med. Res."},{"key":"76256_CR36","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ijcard.2017.05.032","volume":"243","author":"A Di Franco","year":"2017","unstructured":"Di Franco, A. et al. Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target. Int. J. Cardiol. 243, 86\u201390. https:\/\/doi.org\/10.1016\/j.ijcard.2017.05.032 (2017).","journal-title":"Int. J. Cardiol."},{"key":"76256_CR37","doi-asserted-by":"publisher","first-page":"251","DOI":"10.4070\/kcj.2020.0303","volume":"51","author":"SY Lee","year":"2021","unstructured":"Lee, S. Y. et al. Sodium\/glucose co-transporter 2 inhibitor, empagliflozin, alleviated transient expression of SGLT2 after myocardial infarction. Korean Circ. J. 51, 251\u2013262. https:\/\/doi.org\/10.4070\/kcj.2020.0303 (2021).","journal-title":"Korean Circ. J."},{"key":"76256_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 372, n71. https:\/\/doi.org\/10.1136\/bmj.n71 (2021).","journal-title":"BMJ."},{"key":"76256_CR39","unstructured":"Mitsubishi Tanabe Pharma Corporation. CANAGLU 100 mg tablets (Canagliflozin Hydrate) CTD. CTD 2.7.2. (2014)."},{"key":"76256_CR40","unstructured":"Nippon Boehringer Ingelheim CL. Jardiance 10 mg\/25 mg tablets CTD (Empagliflozin). CTD 2.7.2. (2014)."},{"key":"76256_CR41","unstructured":"TAISHO PHARMACEUTICAL HOLDINGS CO. L. Lusefi 2.5 mg\/5 mg tablets CTD (Luseogliflozin Hydrate). CTD 2.7.2. (2014)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76256-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76256-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76256-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T10:04:36Z","timestamp":1729505076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76256-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["76256"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-76256-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]},"assertion":[{"value":"27 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hideki Yoshioka and Akihiro Hisaka work for the Pharmaceuticals and Medical Devices Agency (Tokyo, Japan)\u00a0at present, but the views expressed in this article are those of the authors and do not necessarily reflect the official views of the Pharmaceuticals and Medical Devices Agency. Yamato Sano is an employee of Pfizer R&D Japan. However, Pfizer R&D Japan is not involved in the analysis of this study. There is no conflict of interest to be disclosed for other authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24695"}}